A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye (Q37304878)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 July 2007

Language	Label	Description	Also known as
English	A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye	scientific article published on 20 July 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive mye (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

8

object named as

Mario Sznol

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

Judith E Karp

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Francis J Giles

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Ivana Gojo

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Lawrence Morris

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Jacqueline Greer

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Bonny Johnson

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Mya Thein

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Jennifer Low

9

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

publication date

20 July 2007

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Leukemia Research

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

32

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

71-77

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Polycythemia vera: myths, mechanisms, and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

6 September 2017

Structure and function of the radical enzyme ribonucleotide reductase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

6 September 2017

IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

6 September 2017

Central nervous system toxicity of fludarabine phosphate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

6 September 2017

Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

6 September 2017

Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

6 September 2017

Hydroxyurea in the management of the hematologic complications of chronic granulocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

6 September 2017

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

14 September 2017

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

28 September 2017

In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

28 September 2017

A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

28 September 2017

Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

28 September 2017

Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

28 September 2017

Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

26 June 2018

Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

26 June 2018

Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

26 June 2018

Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

26 June 2018

Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

2 September 2018

Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

2 September 2018

Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

2 September 2018

Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2726775

2 September 2018

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17640728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthesis and biological activity of 3- and 5-amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone

1 reference

https://pubmed.ncbi.nlm.nih.gov/17640728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/17640728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17640728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/17640728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/17640728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanism of synergistic cell killing by hydroxyurea and cytosine arabinoside

1 reference

https://pubmed.ncbi.nlm.nih.gov/17640728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/17640728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers

1 reference

https://pubmed.ncbi.nlm.nih.gov/17640728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17640728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators

1 reference

https://pubmed.ncbi.nlm.nih.gov/17640728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without gran

1 reference

https://pubmed.ncbi.nlm.nih.gov/17640728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones

1 reference

https://pubmed.ncbi.nlm.nih.gov/17640728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzymatic assay for quantification of deoxynucleoside triphosphates in human cells exposed to antiretroviral 2',3'-dideoxynucleosides

1 reference

https://pubmed.ncbi.nlm.nih.gov/17640728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of deoxyribonucleotide synthesis by pyridine carboxaldehyde thiosemicarbazones

1 reference

https://pubmed.ncbi.nlm.nih.gov/17640728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/17640728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/17640728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.LEUKRES.2007.05.003

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37304878&oldid=1403365886"